Research programme: gene therapies - Genethon/Selecta Biosciences

Drug Profile

Research programme: gene therapies - Genethon/Selecta Biosciences

Alternative Names: SEL 302; SEL 313

Latest Information Update: 25 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Genethon; Selecta Biosciences
  • Class Gene therapies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Inborn urea cycle disorders; Methylmalonic acidaemia
  • Research Liver disorders; Muscular dystrophies

Most Recent Events

  • 09 Aug 2016 Preclinical trials in Inborn urea cycle disorders in USA (Parenteral)
  • 09 Aug 2016 Preclinical trials in Methylmalonic acidaemia in USA (Parenteral)
  • 13 May 2015 Early research in Muscular dystrophies and Liver disorders/Metabolic disorders (paediatric liver metabolic diseases) in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top